<p><br></p><div class="text-info"><p>Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.</p><p> </p><p>Our lead product, NTCELL<sup><font size="2">®</font></sup>, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.</p><p> </p><p>A Phase IIb trial of NTCELL for Parkinson's disease is currently underway. It aims to confirm‎ the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful LCT will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.</p><p> </p><p>In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).</p><p> </p><p>LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.</p><p> </p><p>LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.</p></div><div class="home-tab"><div class="nav-bar"><div class="nav-bar-tab inline-block pointer-cursor"><div class="nav-bar-left pink">Announcements</div></div> <div class="nav-bar-tab inline-block pointer-cursor"><div class="nav-bar-middle">LCT in the News</div></div> <div class="nav-bar-tab inline-block pointer-cursor"><div class="nav-bar-right">Events</div></div> <img class="pink-arrow pink-arrow-left show" src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxarrow-pink.png.pagespeed.ic.2R054lPWsp.png"></div><div class="announcements"><div data-query="section=news-asx-announcements"><div class="element-1 "><div class="time uppercase"><p>— 23 June 2016</p></div><div class="title-size"><p>NTCELL® trial results to be presented in Berlin</p></div><div class="text-move-down"><div class="mark" data-full="<p>As advised in our 7 June<strong> </strong>announcement of the trial results,<strong> </strong>Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson&rsquo;s disease at the 20<sup>th</sup> International Congress of Parkinson&rsquo;s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled &ldquo;Safety and clinical effects of NTCELL<sup>&reg;</sup> [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up&rdquo; takes place at 12 noon Berlin time today.</p> <p>&nbsp;</p> <p>Dr Snow, Principal Investigator for the trial, said, &ldquo;This data shows a striking and significant improvement in all measurements of Parkinson&rsquo;s disease in the four patients. Everything we measured has improved.&rdquo;</p> <p>&nbsp;</p> <p>Dr Ken Taylor, CEO of LCT, said, &ldquo;The results of this clinical trial are consistent with what LCT has found in pre-clinical studies. Moreover microarray analyses identified that several nerve growth factors and nerve protective agents are released from NTCELL and this may explain the improvement observed in all of the measurements of Parkinson&rsquo;s disease.&rdquo;</p> <p>&nbsp;</p> <p>The poster is available to view <a href="http://www.lctglobal.com/upload/artwork/LCT%20Parkinsons%20congress%20NTCELL%20abstract%20poster%202016%20final.pdf">here</a>.</p>"><p>As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.</p></div><a class="pink line-decoration right font-600 read show">Read More</a><a class="pink line-decoration right font-600 close hide">Read Less</a> </div><div><img class="left" src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxsave-icon.png.pagespeed.ic.a3S6jFmqN_.png"><a class="pink line-decoration left font-500 move-left" href="http://www.lctglobal.com/upload/news/2016/160623%20NTCELL%20trial%20results%20to%20be%20presented%20in%20Berlin%20ASX.pdf" target="_blank"><u><font color="#0066cc">Download the PDF Version</font></u></a> </div></div><div class="element-1 "><div class="time uppercase"><p>— 8 June 2016</p></div><div class="title-size"><p>Appendix B</p></div><div class="text-move-down"><div class="mark" data-full=""><p>New issue announcement, application for quotation of additional securities and agreement</p></div><a class="pink line-decoration right font-600 read show">Read More</a><a class="pink line-decoration right font-600 close hide">Read Less</a> </div><div><img class="left" src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxsave-icon.png.pagespeed.ic.a3S6jFmqN_.png"><a class="pink line-decoration left font-500 move-left" href="http://www.lctglobal.com/upload/news/2016/160608%20%20Appendix%203B.pdf" target="_blank"><u><font color="#0066cc">Download the PDF Version</font></u></a> </div></div></div><div class="loading-button">Load More </div></div><div class="news"><div data-query="section=news-lct-in-the-news"><div class="element-1 last"><div class="time uppercase"><p>— 1 March 2016</p></div><div class="title-size"><p>LCT expects crucial Parkinson’s clinical trial results in early 2017</p></div><div class="text-move-down"><div class="mark" data-full='<p>Read the full article at <a href="http://www.nbr.co.nz/article/living-cell-expects-crucial-parkinsons-clinical-trial-results-early-2017-b-185558">National Business Review</a></p>'><p>Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.</p></div><a class="pink line-decoration right font-600 read show">Read More</a><a class="pink line-decoration right font-600 close hide">Read Less</a> </div></div></div></div><div class="milestone"><div class="lct-content"><div class="calender-container"><div data-query="section=news-upcoming-events"><div class="item last"><div class="left-icon"><img src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxmile-icon.png.pagespeed.ic.f8DBJsHJ0_.png"> </div><div class="right-info"><div class="title-time uppercase">— 23 June 2016</div><div class="main-info"><p><strong>20th International Congress of Parkinson’s Disease and Movement Disorders.</strong> Principal Investigator Barry Snow, MD is presenting a poster at the Congress Scientific Program Committee of the 20th International Congress of Parkinson’s Disease and Movement Disorders, in Berlin, Germany. The details of the poster presentation are as follows: Abstract number: 1952 Abstract title: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up Poster session topic: Parkinson's disease: Clinical trials, pharmacology and treatment Presentation Date: 23 June 2016 Presentation time: 12:00 – 13:30 Location: Exhibit Hall located in Hall B, Level 2 City Cube Berlin Messe Berlin GmbH Messedamm 22 14055 Berlin Germany</p></div></div></div></div></div></div></div></div><div class="accordion-wrapper"><dl class="accordion"><dt><a href=""><u><font color="#0066cc">Announcements</font></u></a> </dt><dd style="display: none;"><div class="announcements"><div data-query="section=news-asx-announcements"><div class="element-1 "><div class="time uppercase"><p>— 23 June 2016</p></div><div class="title-size"><p>NTCELL® trial results to be presented in Berlin</p></div><div class="text-move-down"><div class="mark" data-full="<p>As advised in our 7 June<strong> </strong>announcement of the trial results,<strong> </strong>Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson&rsquo;s disease at the 20<sup>th</sup> International Congress of Parkinson&rsquo;s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled &ldquo;Safety and clinical effects of NTCELL<sup>&reg;</sup> [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up&rdquo; takes place at 12 noon Berlin time today.</p> <p>&nbsp;</p> <p>Dr Snow, Principal Investigator for the trial, said, &ldquo;This data shows a striking and significant improvement in all measurements of Parkinson&rsquo;s disease in the four patients. Everything we measured has improved.&rdquo;</p> <p>&nbsp;</p> <p>Dr Ken Taylor, CEO of LCT, said, &ldquo;The results of this clinical trial are consistent with what LCT has found in pre-clinical studies. Moreover microarray analyses identified that several nerve growth factors and nerve protective agents are released from NTCELL and this may explain the improvement observed in all of the measurements of Parkinson&rsquo;s disease.&rdquo;</p> <p>&nbsp;</p> <p>The poster is available to view <a href="http://www.lctglobal.com/upload/artwork/LCT%20Parkinsons%20congress%20NTCELL%20abstract%20poster%202016%20final.pdf">here</a>.</p>"><p>As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.</p></div><a class="pink line-decoration right font-600 read show">Read More</a><a class="pink line-decoration right font-600 close hide">Read Less</a> </div><div><img class="left" src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxsave-icon.png.pagespeed.ic.a3S6jFmqN_.png"><a class="pink line-decoration left font-500 move-left" href="http://www.lctglobal.com/upload/news/2016/160623%20NTCELL%20trial%20results%20to%20be%20presented%20in%20Berlin%20ASX.pdf" target="_blank"><u><font color="#0066cc">Download the PDF Version</font></u></a> </div></div><div class="element-1 "><div class="time uppercase"><p>— 8 June 2016</p></div><div class="title-size"><p>Appendix B</p></div><div class="text-move-down"><div class="mark" data-full=""><p>New issue announcement, application for quotation of additional securities and agreement</p></div><a class="pink line-decoration right font-600 read show">Read More</a><a class="pink line-decoration right font-600 close hide">Read Less</a> </div><div><img class="left" src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxsave-icon.png.pagespeed.ic.a3S6jFmqN_.png"><a class="pink line-decoration left font-500 move-left" href="http://www.lctglobal.com/upload/news/2016/160608%20%20Appendix%203B.pdf" target="_blank"><u><font color="#0066cc">Download the PDF Version</font></u></a> </div></div></div><div class="loading-button">Load More </div></div></dd><dt><a href=""><u><font color="#0066cc">LCT in the News</font></u></a> </dt><dd style="display: none;"><div class="news"><div data-query="section=news-lct-in-the-news"><div class="element-1 last"><div class="time uppercase"><p>— 1 March 2016</p></div><div class="title-size"><p>LCT expects crucial Parkinson’s clinical trial results in early 2017</p></div><div class="text-move-down"><div class="mark" data-full='<p>Read the full article at <a href="http://www.nbr.co.nz/article/living-cell-expects-crucial-parkinsons-clinical-trial-results-early-2017-b-185558">National Business Review</a></p>'><p>Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.</p></div><a class="pink line-decoration right font-600 read show">Read More</a><a class="pink line-decoration right font-600 close hide">Read Less</a> </div></div></div></div></dd><dt><a href=""><u><font color="#0066cc">Events</font></u></a> </dt><dd style="display: none;"><div class="milestone"><div class="lct-content"><div class="calender-container"><div data-query="section=news-upcoming-events"><div class="item last"><div class="left-icon"><img src="https://img1.daumcdn.net/relay/cafe/original/?fname=http%3A%2F%2Fwww.lctglobal.com%2Fimages%2Fxmile-icon.png.pagespeed.ic.f8DBJsHJ0_.png"> </div><div class="right-info"><div class="title-time uppercase">— 23 June 2016</div><div class="main-info"><p><strong>20th International Congress of Parkinson’s Disease and Movement Disorders.</strong> Principal Investigator Barry Snow, MD is presenting a poster at the Congress Scientific Program Committee of the 20th International Congress of Parkinson’s Disease and Movement Disorders, in Berlin, Germany. The details of the poster presentation are as follows: Abstract number: 1952 Abstract title: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up Poster session topic: Parkinson's disease: Clinical trials, pharmacology and treatment Presentation Date: 23 June 2016 Presentation time: 12:00 – 13:30 Location: Exhibit Hall located in Hall B, Level 2 City Cube Berlin Messe Berlin GmbH Messedamm 22 14055 Berlin Germany</p></div></div></div></div></div></div></div></dd></dl></div><div class="footer"><div class="footer-content "><div class="footer-right"><div class="footer-list"><p class="font-12 bold">About LCT</p><p>-</p><ul class="font-12 no-bullet line-decoration"><li><a class="grey-links" href="http://www.lctglobal.com/about-lct/history"><u><font color="#0066cc">History</font></u></a></li><li><a class="grey-links" href="http://www.lctglobal.com/about-lct/lct-today"><u><font color="#0066cc">LCT today</font></u></a></li><li><a class="grey-links" href="http://www.lctglobal.com/about-lct/fact-sheets"><u><font color="#0066cc">Fact sheets</font></u></a></li></ul><p class="font-12 bold footer-p-move-down">News and Events</p><p>-</p><ul class="font-12 no-bullet line-decoration"><li><a class="grey-links" href="http://www.lctglobal.com/news/asx-announcements"><u><font color="#0066cc">ASX announcements</font></u></a></li><li><a class="grey-links" href="http://www.lctglobal.com/news/other-news"><u><font color="#0066cc">Other news</font></u></a></li><li><a class="grey-links" href="http://www.lctglobal.com/news/lct-in-the-news"><u><font color="#0066cc">LCT in the news</font></u></a></li><li><a class="grey-links" href="http://www.lctglobal.com/news/upcoming-events"><u><font color="#0066cc">Upcoming events</font></u></a></li><li><a class="grey-links" href="http://www.lctglobal.com/news/presentations"><u><font color="#0066cc">Recent Presentations</font></u></a></li></ul></div><br></div></div></div>
<!-- -->
@푸른희망(Sharon)희망님께 조국의 파환우들께 많은 도움이 되어주시는 항해의 등대와 같은 희망님, 똑소리나는 글과 지적인 감성이 두드러진 님은 무한이 27년의 인고의 투병 생활의 승리자 이십니다 님의 동영상 목소리를 듣기전까지만 해도 희망님은 어데 아픈데라고는 하나도 없는 분이신줄 착각 했습니다 카페에서의 활동은 그랬습니다 목소리를 듣는순간 마음이 아팠습니다 환자였어요 그럼에도 불구하고 조국의 환우들을 위해 애쓰심 감사합니다 고맙습니다 감사합니다 사랑합니다
첫댓글 ㅎ 나중에 알았습니다^^
@푸른희망(Sharon) 희망님께
조국의 파환우들께 많은 도움이 되어주시는
항해의 등대와 같은 희망님,
똑소리나는 글과 지적인 감성이 두드러진 님은 무한이 27년의 인고의 투병 생활의 승리자 이십니다 님의 동영상 목소리를 듣기전까지만 해도 희망님은 어데 아픈데라고는 하나도 없는
분이신줄 착각 했습니다
카페에서의 활동은 그랬습니다
목소리를 듣는순간 마음이 아팠습니다
환자였어요
그럼에도 불구하고 조국의 환우들을 위해
애쓰심 감사합니다
고맙습니다 감사합니다 사랑합니다